

## Golotimod

## Chemical Properties

CAS No. : 229305-39-9

Formula: C<sub>16</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>


Molecular Weight: 333.34

Keep away from direct sunlight, Keep away from moisture

Storage:

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Golotimod (SCV 07) is an antimicrobial dipeptide with immunomodulatory activity that significantly improves the efficacy of anti-tuberculosis therapy, induces thymic and splenic cell proliferation, modulates macrophage function, and inhibits STAT3 signaling. Golotimod has been used in the study of recurrent genital Herpes Simplex Virus 2 (HSV-2) infection and oral mucositis.
Targets(IC50)	Antibacterial, Antibiotic, STAT
In vivo	In female Hartley guinea pigs (250-300 g) infected with HSV-2, Golotimod (100 µg/kg; oral gavage or subcutaneous injection; 5 days) reduced the incidence of lesions from 55% (one week before treatment) to only 18% by oral administration[1].

## Solubility Information

Solubility	H <sub>2</sub> O: 100 mg/mL (299.99 mM), Sonification is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9999 mL	14.9997 mL	29.9994 mL
5 mM	0.600 mL	2.9999 mL	5.9999 mL
10 mM	0.300 mL	1.500 mL	2.9999 mL
50 mM	0.060 mL	0.300 mL	0.600 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). *Int J Antimicrob Agents*. 2008 Sep;32(3):262-6.

Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. *Oral Oncol*. 2016 May;56:84-92.

Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). *Oral Dis*. 2010 Oct;16(7):655-60.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481